Pfizer and GSK to compete for $120 million Russian pneumococcal vaccine contract
US pharma giant Pfizer (NYSE) and UK peer GlaxoSmithKline (LSE: GSK) plan to compete for the 3.47 billion-rouble ($120 million) contract in Russia for the supply of pneumococcal vaccines for state needs, reports The Pharma Letter’s Russia correspondent.
It is planned that the tender for the supply of 2.89 million doses of vaccine will be organized by the Russian Ministry of Health by the end of the current year.
According to initial plans of the Ministry, Pfizer (with its Prevenar 13 pneumococcal vaccine) was to have been a single bidder for the contract, while GSK’s Synflorix was not allowed to participate in the tender, due to non-compliance with some of its requirements. However a few months later, the Russian Federal Antimonopoly Service issued a clarification, which recognized Pfizer and GSK vaccines partially interchangeable. This provided an opportunity for GSK to participate in the tender.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze